EuroEspes Biotechnology Nutraceutical Ingredients for Dietary Supplement Development

EuroEspes Biotechnology (Ebiotec) develops novel bioproducts to prevent and treat diseases such as brain disorders, cancer and metabolic syndromes.

The company uses its 28-year-experience in genomics, pharmacogenetics, nutrigenetics and epigenetics to provide personalised medicine, unique for every patient.

Since it was founded, Ebiotec has developed four lines of nutraceutical bioproducts derived from marine (‘lipofishins’ and ‘proteolipins’), vegetal (favalins), animal (nootropins) and hybrid sources.

Lipofishins are a new type of lipoproteins that are found in several different fish species. While proteolipins are a new variety of nutraceutical compounds that are extracted from natural sources. Both lipofishins and proteolipins have been proven to be effective in various therapeutic treatments.

Natural nutraceutical bioproducts for drug developers

Ebiotec’s nutraceuticals are obtained from natural sources, extracted by biotechnological procedures to preserve the properties of their ingredients or active principles.

The biological properties of the nutraceuticals are supported by both preclinical and clinical studies.

Major lines of investigation include neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases; cardiovascular and related disorders; cancer; metabolic disorders; and other pathologies such as liver dysfunction, gastrointestinal and immune diseases.

Marine-based nutritional supplement for cardiovascular health

LipoEsar (E-SAR-94010) is a lipofishin extracted from the species Sardina pilchardus (European pilchard).

LipoEsar is shown to be effective in reducing cholesterol, triglyceride, uric acid and glucose levels. The extract was found to decrease liver alanine aminotransferase and aspartate aminotransferase activity.

This nutraceutical enhances immunological function by regulating both lymphocyte and microglia activity and induces antioxidant effects mediated by superoxidase dismutase activity.

LipoEsar has been proven to improve cardiovascular, cerebrovascular and cognitive functions.

Metabolism-enhancing supplement to prevent bioenergetic and nutritional deficiency

CabyMar (E-CAB-94011) is a nutraceutical obtained from the species Scomber scombrus (Atlantic mackerel).

Featuring anti-oxidant, anti-inflammatory and bio-energising properties, this supplement is used to treat medical conditions such as anaemia, muscle disorders, alterations in growth and development, vascular diseases, and neurodegenerative disorders.

CabyMar is used to maintain the immune system, increase energy, optimise cardiovascular health and reduce plasma transaminase levels in the liver. It is suitable for athletes experiencing physical or mental strain, and those suffering from stress or fatigue.

Immunomodulatory medicine for immune deficiency and microbial infections

DefenVid (E-JUR-94013) is a lipofishin derived from the species Trachurus trachurus (Atlantic horse mackerel).

This nutraceutical supplement has anti-inflammatory and immune-enhancing properties for cases of immunodeficiency, microbial infections and diseases caused by a weakened immune system.

DefenVid is designed for people experiencing weakness, fatigue and physical/mental stress. It helps the body build resilience against chills and colds by strengthening the immune system.

Anti-tumoural bioproduct to strengthen the immune system

AntiGan (E-Congerine-10423) is a lipofishin extracted from the species Conger conger (European conger).

This compound displays a powerful anti-tumoural effect in many different tumour cell lines, with specific effects on some solid tumours, sarcomas, liposarcomas, ulcerative colitis and Crohn’s disease.

AntiGan works as an immunomodulatory agent by upregulating immune function via increased expression of CD4 and CD28 antigens in T lymphocytes.

Nutritional supplement to normalise menopause symptoms

Mineraxin (E-MHK-0103) is a proteolipin derived from the Mediterranean mussel (Mytilus galloprovincialis).

This bioproduct regulates hypothalamus-pituitary hormones and influences growth and development.

Mineraxin modulates bone metabolism, acting as a powerful anti-osteoporotic agent and prevents the onset of menopause symptoms.

Vegetal-based medicine for dopamine deficiency in Parkinson’s disease

Atremorine (E-PodoFavalin-15999) is a novel biopharmaceutical compound extracted from Vicia faba L.

This nutraceutical is designed for the prevention of Parkinson’s disease. It works on dopamine deficiency associated pathologies, protecting cells against oxidative stress and neurodegeneration.

Atremorine helps improve motor function, while protecting DNA, proteins and lipids.

Personalised medicines for pharmacogenetic treatments

The EuroEspes Group has developed the world’s first smart pharmacogenetic card. This digital card holds information such as patient’s metabolic rate, specific hereditary risk factors and present epigenetic biomarkers. Its main purpose is to provide key information about the patient for a personalised treatment, helping physicians to treat every patient as unique.

The company has edited the World Guide for Drug Use and Pharmacogenomics and the EuroPharmaGenics database.

The company offers industrial lyophilisation services for third-parties in the pharmaceutical and nutrition industries.

Ebiotec provides primary screening of drugs and bioproducts, vaccine development, preclinical and toxicological studies, clinical trials and CRO partnership. Alongside this, the company rears transgenic animals to develop new treatments for neurodegenerative disorders.

About Ebiotec

Ebiotec is part of the EuroEspes Group, a biomedical organisation headquartered at the EuroEspes Biomedical Research Centre in Corunna, Spain.

The EuroEspes Group was founded in 1991 by Professor Ramon Cacabelos, who is the president of the board of directors.

The EuroEspes Group provides personalised medical services specialised in brain disorders and genomic medicine.

EuroEspes Medical Centre has treated patients worldwide ever since it was founded.

Make an enquiry

Press Release

AtreMorine for Parkinson’s Disease and Dopamine-Related Disorders

AtreMorine is a novel biopharmaceutical compound obtained through non-denaturing biotechnological procedures from the structural components of the Vicia faba L plant, for the prevention and treatment of Parkinson´s disease (PD) and related disorders.

EuroEspes Biotechnology Images

Products and Services

Video

White Papers

Related Projects



Press Release

23rd October 2019

AtreMorine is a novel biopharmaceutical compound obtained through non-denaturing biotechnological procedures from the structural components of the Vicia faba L plant, for the prevention and treatment of Parkinson´s disease (PD) and related disorders.

Read more
Close
Close
Close

Go Top